Q1 2025 Globus Medical Inc Earnings Call Transcript
Key Points
- Globus Medical Inc (GMED) achieved a significant increase in free cash flow, reaching $141 million, which is a 493% increase compared to the previous year.
- The company successfully returned to a debt-free status by paying off nearly $900 million of debt inherited from the NuVasive merger.
- Globus Medical Inc (GMED) launched two new products in Q1, which are expected to drive market penetration and enhance their product portfolio.
- The US spine business showed resilience with a 2% growth in Q1, driven by high retention rates and strong product offerings.
- The acquisition of Nevro Corporation is seen as a strategic move to expand into a $3 billion market space, enhancing Globus Medical Inc (GMED)'s reach in the musculoskeletal market.
- Globus Medical Inc (GMED) experienced a slight decline in Q1 revenue, down 0.8% on a constant currency basis, due to softer enabling technology sales and supply chain disruptions.
- The company faced temporary integration-related supply chain disruptions, impacting sales and causing back orders.
- Enabling technology sales decreased by 31% compared to the previous year, attributed to an elongated selling cycle and market uncertainty.
- The international spine implant business grew only 1% in Q1, affected by the timing of distributor orders and supply chain issues.
- The combined trauma and NSO business declined by 8% in Q1, primarily due to integration-related supply chain disruptions.
Welcome to the Globus Medical's first quarter 2025 earnings call. (Operator Instructions)
I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations.
Thank you, Brianna, and thank you everyone for being with us today. Joining today's call from Globus Medical will be Dan Scavilla, President and CEO, and Keith Pfeil, Chief Operating Officer and Chief Financial Officer.
This review is being made available via webcast, accessible through the investor relations section of the Globus Medical website at globusmedical.com. Before we begin, let me remind you that some of the statements made during this review are or may be considered forward-looking statements.
Our Form 10-K for the 2024 fiscal year and our subsequent filings with the Securities and Exchange Commission identify certain factors that could cause our actual results to differ materially from those projected in any forward-looking statements made today.
Our SEC
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
